Abstract
Cytokine storms and hyperinflammation, potentially controlled by glucocorticoids, occur in COVID-19; the roles of lipid mediators and acetylcholine (ACh) and how glucocorticoid therapy affects their release in Covid-19 remain unclear. Blood and bronchoalveolar lavage (BAL) samples from SARS-CoV-2- and non-SARS-CoV-2- infected subjects were collected for metabolomic/lipidomic, cytokines, soluble CD14 (sCD14), and ACh, and CD14 and CD36-expressing monocyte/macrophage subpopulation analyses. Transcriptome reanalysis of pulmonary biopsies was performed by assessing coexpression, differential expression, and biological networks. Correlations of lipid mediators, sCD14, and ACh with glucocorticoid treatment were evaluated. This study enrolled 190 participants with Covid-19 at different disease stages, 13 hospitalized non-Covid-19 patients, and 39 healthy-participants. SARS-CoV-2 infection increased blood levels of arachidonic acid (AA), 5-HETE, 11-HETE, sCD14, and ACh but decreased monocyte CD14 and CD36 expression. 5-HETE, 11-HETE, cytokines, ACh, and neutrophils were higher in BAL than in circulation (fold-change for 5-HETE 389.0; 11-HETE 13.6; ACh 18.7, neutrophil 177.5, respectively). Only AA was higher in circulation than in BAL samples (fold-change 7.7). Results were considered significant at P<0.05, 95%CI. Transcriptome data revealed a unique gene expression profile associated with AA, 5-HETE, 11-HETE, ACh, and their receptors in Covid-19. Glucocorticoid treatment in severe/critical cases lowered ACh without impacting disease outcome. We first report that pulmonary inflammation and the worst outcomes in Covid-19 are associated with high levels of ACh and lipid mediators. Glucocorticoid therapy only reduced ACh, and we suggest that treatment may be started early, in combination with AA metabolism inhibitors, to better benefit severe/critical patients.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This is an observational study.
Funding Statement
FAPESP: #2020/05207-6, #2014/07125-6 and #2015/00658-1 for L.H.F.; #2020/08534-8 for M.M.P.; #2018/22667-0 for C.O.S.S.; #2020/05270-0 for V.D.B. additional support was given by the National Council for Scientific and Technological Development (CNPq); #302514/2015-5-CNPq for L.H.F.; #312606/2019-2-CNPq for M.D.B. and #309583/2019-5-CNPq for C.R.B.C.; the Coordination for the Improvement of Higher Educational Personnel (CAPES-Finance Code 001), and grant-USP-VIDA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The entire study was approved by two Brazilian ethics oversight body: <em>i</em>) a local Committee, <em>Comitê de Ética em Pesquisa</em> from <em>Faculdade de Ciências Farmacêuticas de Ribeirão Preto</em> of the <em>Universidade de São Paulo</em> (CEP-FCFRP-USP - <a href="https://fcfrp.usp.br/en/institucional/comissoes/comite-etica-pesquisa/"><span lang="en-US">https://fcfrp.usp.br/en/institucional/comissoes/comite-etica-pesquisa/</span></a> - E-mail: cep@fcfrp.usp.br), coordinated by Prof. Dr. Cleni Mara Marzocchi Machado, Ph.D.; <em>ii</em>) a national Committee, <em>Conselho Nacional de Pesquisa em Humanos</em> (CONEP - <a href="https://plataformabrasil.saude.gov.br/login.jsf"><span lang="en-US">https://plataformabrasil.saude.gov.br/login.jsf</span></a> - E-mail: conep@saude.gov.br), coordinated by Jorge Alves de Almeida Venâncio, M.D., Ph.D. The research protocol (first approval document) and four amendments were approved and received the certificate of Presentation and Ethical Appreciation (CAAE: 30525920.7.0000.5403). We are sending an Ethical Approval Statement as a supplemental material, please see enclosed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data can be requested by email: faccioli@fcfrp.usp.br
